

National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic

Palmateer, N.E.; Dickson, E.; Furrie, E.; Godber, I.; Goldberg, D. J.; Gousias, P.; Jarvis, L.; Mathie, L.; Mavin, S.; McMenamin, J.; McNeilly, T. N.; Murcia, P.; Murray, J.; Reid, G.; Robertson, C.; Templeton, K.; Von Wissman, B.; Wallace, L.A.; Waugh, C.; McAuley, Andrew

Published in:
Public Health

DOI:
[10.1016/j.puhe.2021.07.006](https://doi.org/10.1016/j.puhe.2021.07.006)

Publication date:
2021

Document Version
Author accepted manuscript

[Link to publication in ResearchOnline](#)

Citation for published version (Harvard):

Palmateer, NE, Dickson, E, Furrie, E, Godber, I, Goldberg, DJ, Gousias, P, Jarvis, L, Mathie, L, Mavin, S, McMenamin, J, McNeilly, TN, Murcia, P, Murray, J, Reid, G, Robertson, C, Templeton, K, Von Wissman, B, Wallace, LA, Waugh, C & McAuley, A 2021, 'National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic', *Public Health*, vol. 198, pp. 102-105. <https://doi.org/10.1016/j.puhe.2021.07.006>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please view our takedown policy at <https://edshare.gcu.ac.uk/id/eprint/5179> for details of how to contact us.

1 **Title:** National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and
2 second waves of the COVID-19 pandemic

3

4 **Abstract**

5 *Objectives:* Studies that measure the prevalence of antibodies to SARS-CoV-2 (“seroprevalence”) are
6 essential to understand population exposure to SARS-CoV-2 among symptomatic and asymptomatic
7 individuals. We aimed to measure seroprevalence in the Scottish population over the course of the
8 COVID-19 pandemic – from prior to the first recorded case in Scotland, through to the second pandemic
9 wave.

10 *Study design:* Serial cross-sectional.

11 *Methods:* We tested 41,477 residual samples retrieved from primary and antenatal care settings across
12 Scotland for SARS-CoV-2 antibodies over a 12-month period from December 2019-December 2020 (pre-
13 rollout of COVID-19 vaccination). Five-weekly rolling seroprevalence estimates were adjusted for the
14 sensitivity and specificity of the assays and weighted to reference populations. Temporal trends in
15 seroprevalence estimates and weekly SARS-CoV-2 PCR positive notifications were compared.

16 *Results:* Five-weekly rolling seroprevalence rates were 0% until the end of March, when they increased
17 contemporaneously with the first pandemic wave. Seroprevalence rates remained stable through the
18 summer (range 3%-5%) during a period of social restrictions, following which they increased
19 concurrently with the second wave, reaching 9.6% (95% CI 8.4%-10.8%) in week beginning 28th
20 December 2020. Seroprevalence rates were lower in rural vs. urban areas (adjusted odds ratio[AOR]
21 0.70, 95% CI 0.61-0.79) and among individuals aged 20-39 and 60+ (AORs 0.74, 95% CI 0.64-0.86, and
22 0.80, 95% CI 0.69-0.91, respectively) relative to those aged 0-19 years.

23 *Conclusions:* After two waves of the COVID-19 pandemic, less than one in ten individuals in the Scottish
24 population had antibodies to SARS-CoV-2. Seroprevalence may underestimate the true population
25 exposure as a result of waning antibodies among individuals who were infected early in the first wave.

26 **Keywords:** SARS-CoV-2, COVID-19, seroprevalence, antibodies, cross-sectional

27

28 **Text word count: 1,475**

29 The first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Scotland was
30 reported on 1 March 2020. The country has since experienced two waves of COVID-19 (the disease
31 associated with SARS-CoV-2), which has resulted in one of the highest excess mortality rates worldwide.
32 Estimates of the proportion of individuals in the population who have been exposed to SARS-CoV-2 –
33 both symptomatic and asymptomatic – are necessary to understand the progression of the pandemic to
34 date. Since PCR testing in the general population until recently has mainly been limited to those with
35 symptoms, seroprevalence studies, which measure antibodies to SARS-CoV-2, provide a means of
36 measuring population exposure. Furthermore, it is essential to have estimates of the extent of exposure
37 from wild-type infection prior to rollout of vaccination. Most population-based seroprevalence surveys
38 to date have focused on short time frames or sub-national populations; here, we examine serial cross-
39 sectional estimates of seroprevalence over a 12-month period in the Scottish general population, using
40 residual blood samples from different sources.

41 Residual blood samples, originally collected for other purposes, were identified from primary care (i.e.
42 general practice) and antenatal care settings. Antenatal samples were retrospectively identified at
43 regional laboratories across Scotland that store specimens taken for infectious disease screening at
44 week 12 of pregnancy; these specimens are submitted from all antenatal settings in the regional health
45 authority areas (“National Health Service (NHS) Boards”) that are covered by these laboratories.

46 Samples were available from ISO-week 1 (week beginning (w/b) 30th December 2019), to ISO-week 26
47 (w/b 29th June 2020); all available samples with sufficient volume were included (totaling 16,157).

48 Primary care samples were retrieved from regional laboratories, which receive samples from general
49 practices across the NHS Boards that they cover. Approximately 700 weekly samples were obtained
50 between ISO week 17 (w/b 20th April 2020) and ISO-week 53 (w/b 28th December 2020), totaling 25,320

51 samples. Primary care samples were selected according to an age/sex/NHS Board sampling frame
52 corresponding to the Scottish general population structure. Eleven and seven out of the 14 NHS Boards
53 in Scotland participated in the primary care and antenatal surveillance, respectively, covering 91% and
54 73% of the Scottish population. This analysis was restricted to samples up until the end of December
55 2020 in order to measure exposure to wild-type infection and not vaccine response: vaccination rollout
56 for target groups began in Scotland on 8th December 2020; however, given the lag time between
57 exposure to vaccination and seroconversion,^{1,2} antibodies resulting from vaccine response would likely
58 not be detectable in seroprevalence estimates until early January 2021.

59 Samples were anonymised prior to testing: only age (and sex for primary care samples) and NHS Board
60 were attached to the result. Primary care samples were sent to the Scottish Microbiology Reference
61 laboratory, where they were tested for the presence of anti-SARS-CoV-2 IgG antibodies using the
62 LIAISON®SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Italy). Antenatal samples were tested at the regional
63 laboratories where they were stored using either the Abbott (Abbott SARS-CoV-2 N IgG), Roche (Roche
64 Elecsys Anti-SARS-CoV-2 N IgM/ IgG) or Siemens (Siemens Atellica IM 1300 S1 total antibody) assay,
65 depending on the laboratory where testing was undertaken. We identified positive results in the
66 antenatal samples in the weeks prior to the first confirmed case of COVID-19 in Scotland (n=9). While
67 there is evidence to suggest that COVID-19 was circulating before it was first identified in numerous
68 countries,^{3,4} we considered the possibility that these were false positives and therefore confirmatory
69 testing was undertaken by re-testing on a different assay (Roche/Siemens) to the original (Abbott).
70 Samples were re-tested (one re-test per sample) in ascending chronological order until 10 consecutive
71 negative samples were obtained. The confirmatory result is presented here.

72 Local unpublished evaluations determined sensitivities and specificities of the assays (Table 1).

73 Seroprevalence rates were adjusted for sensitivity and specificity,⁵ and weighted to a reference

74 population (the Scottish general population for primary care; maternities in Scotland for antenatal),
75 using bootstrap methods. Five-weekly rolling seroprevalence estimates were calculated to smooth out
76 week-to-week variation; these were plotted against the last week in each five-week grouping (e.g.
77 weeks 17-21 were plotted at week 21). Seroprevalence estimates were compared to SARS-CoV-2 PCR
78 positive notifications obtained from Public Health Scotland. Weekly totals for the latter were plotted
79 against a 3-week lag, to account for the delay between exposure to the virus and seroconversion
80 (estimated to be between 2-4 weeks).⁶ Chi-square tests for trend (χ^2_{trend}) were conducted on the weekly
81 unadjusted seroprevalence data to determine statistical significance. Mantel-Haenszel odds ratios,
82 adjusted for ISO-week, were calculated to examine differences in seroprevalence by sex, age group, and
83 region (categorized into urban/rural) among the primary care samples.

84 Rolling 5-weekly seroprevalence rates (Figure 1a) in the antenatal samples were 0% from ISO weeks 5
85 (w/b Monday 27th January 2020) through to 13 (w/b Monday 23rd March), then subsequently increased
86 from 0.1% (95% CI 0.0%-0.3%) in ISO-week 14 to 2.8% (95% CI 2.2%-3.5%) in ISO-week 20 ($\chi^2_{\text{trend}}=14.72$,
87 $p=0.0001$). The increase in seroprevalence occurred contemporaneously with the increase in SARS-CoV-
88 2 PCR positive cases associated with first wave of the COVID-19 pandemic in Scotland (Figure 1b).

89 Seroprevalence estimates were comparable between the two sources across the weeks where data
90 were available from both (ISO-weeks 21-26). The primary care seroprevalence estimates were stable
91 across the period until approximately ISO-week 43 (w/b 19th October 2020) ($\chi^2_{\text{trend}}=0.41$, $p=0.5241$), at
92 which point there was a sharp increase, reaching 9.6% (95% CI 8.4%-10.8%) in ISO-week 53 (w/b 28th
93 December 2020) ($\chi^2_{\text{trend}}=23.28$, $p<0.001$). This second increase in seroprevalence occurred concurrently
94 with the increase in SARS-CoV-2 cases associated with the second wave of the pandemic (Figure 1b).

95 Seroprevalence rates by sex, age, and region are presented in the supplementary files. Seroprevalence
96 between males and females (Figure S1) was similar across the time series ($p=0.8318$; Table S1).

97 Seroprevalence was lower in the 20-39 and 60+ age groups compared to those aged 0-19 years ($p < 0.001$
98 and $p = 0.0013$, respectively; Table S1, Figure S2). Regional comparisons showed higher seroprevalence in
99 NHS Boards with large urban centres compared to those with primarily rural populations ($p < 0.001$; Table
100 1, Figures S3 and S4).

101 Our findings provide an indication of the general population exposure to SARS-CoV-2 in Scotland, prior
102 to the mass rollout of vaccination. To our knowledge, this is the first study to present national
103 seroprevalence rates over two waves of infection. Our results are consistent with no population
104 exposure in the early months of 2020, and a sharp increase in seroprevalence associated with onset of
105 the first pandemic wave in March 2020. The stable seroprevalence rates thereafter coincide with a
106 period of varying intensity of social restrictions imposed from the first lockdown, on 23rd March, onward.
107 A second sharp increase in seroprevalence was observed from October, coinciding with the second
108 pandemic wave. Our seroprevalence findings are consistent with the PCR data during the period of
109 restrictions from March to October; it is likely that the infection rates across this period, which
110 otherwise would have caused an increase in seroprevalence, were counterbalanced by waning antibody
111 among individuals who had been exposed early on in the pandemic.⁷ We also found that seroprevalence
112 rates were higher in urban areas and in those aged 0-19 years.

113 Despite two waves of infection, our estimate of seroprevalence of 9.6% at the end of December 2020
114 suggests that the majority of the Scottish population has still not been exposed to SARS-CoV-2. This
115 finding is corroborated by seroprevalence data from other western countries in similar phases of the
116 pandemic: a study of blood donors/pregnant women in Stockholm, Sweden, showed approx. 15%
117 seroprevalence by mid-Dec 2020 (this is comparable to our estimates from urban areas such as Greater
118 Glasgow, which approached 13% by end December).⁸ A household survey from Geneva found a slightly
119 higher seroprevalence of 21%.⁹

120 Seroprevalence may, however, underestimate true population exposure for several reasons: lack of
121 antibody persistence⁷ and the role of other immune responses in neutralizing infection (there is
122 evidence that some individuals who are exposed to SARS-CoV-2 do not develop measurable antibodies,
123 suggesting the role of cellular immunity).¹⁰ The ability of binding antibodies to confer immunity to SARS-
124 CoV-2 infection is also not known and antibody neutralisation activity may be less among asymptomatic
125 individuals.¹¹

126 Limitations of our study include the uncertainty in the sensitivity and specificity of the assays, and
127 uncertainty with regard to the representativeness of our samples with regard to the general Scottish
128 population. To address this, we weighted the data to standard reference populations to account for any
129 oversampling according to age/sex/geography; furthermore, primary care results are very consistent
130 with data from a general household survey undertaken across Scotland.¹² The seroprevalence rates from
131 antenatal samples were slightly lower than those from primary care: we hypothesise that pregnant
132 women were taking extra precautions to avoid infection in the context of the COVID-19 pandemic.

133

134 **Author statements**

135 *Acknowledgements:* The authors would like to thank the real-time epidemiology team at Public Health
136 Scotland for the PCR data; staff at all the participating regional laboratories; and the National Serology
137 Strategy Group for their oversight of the study.

138 *Funding:* This work was supported by the Scottish Government. The funding body had no role in the
139 conduct of this analysis or the writing of this manuscript

140 *Competing interests:* PM owns shares of Astra Zeneca. The remaining authors have no competing
141 interests to declare.

142 *Ethical approval:* Approval for the COVID-19 serological surveillance work was given by the Head of
143 Information Governance and Statistical Governance at Public Health Scotland.

144

145 **REFERENCES**

- 146 1. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and
147 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a
148 phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020 Aug 15;396(10249):467–478.
- 149 2. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-
150 19 RNA vaccine BNT162b1 in adults. *Nature*. 2020 Aug 12;586(7830):589–593.
- 151 3. van Dorp L, Acman M, Richard D, Shaw LP, Ford CE, Ormond L, et al. Emergence of genomic
152 diversity and recurrent mutations in SARS-CoV-2. *Infect Genet Evol*. 2020 Sep;83:104351.
- 153 4. Delatorre E, Mir D, Gräf T, Bello G. Tracking the onset date of the community spread of SARS-CoV-
154 2 in western countries. *Mem Inst Oswaldo Cruz*. 2020 Sep 4;115:e200183.
- 155 5. Diggle PJ. Estimating prevalence using an imperfect test. *Epidemiol Res Int*. 2011;2011:1–5.
- 156 6. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral Response to Diagnose
157 Novel Coronavirus Disease (COVID-19). *Clin Infect Dis*. 2020 Jul 28;71(15):778–785.
- 158 7. Hall V, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. Do antibody positive healthcare
159 workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large
160 multi-centre prospective cohort study (the SIREN study), England: June to November 2020.
161 medRxiv. 2021 Jan 15 [cited 2021 Mar 23]. Available from: doi:
162 <https://doi.org/10.1101/2021.01.13.21249642>.
- 163 8. Dopico XC, Muschiol S, Christian M, Hanke L, Sheward DJ, Grinberg NF, et al. Seropositivity in
164 blood donors and pregnant women during 9-months of SARS-CoV-2 transmission in Stockholm,
165 Sweden. medRxiv. 2020 Dec 26 [cited 2021 Mar 23]. Available from: doi:
166 <https://doi.org/10.1101/2020.12.24.20248821>.
- 167 9. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-
168 SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.
169 *Lancet*. 2020;396(10247):313–319.
- 170 10. Doshi P. Covid-19: Do many people have pre-existing immunity? *BMJ*. 2020 Sep 17;370:m3563.
- 171 11. Hughes EC, Amat JAR, Haney J, Parr YA, Logan N, Palmateer N, et al. SARS-CoV-2 serosurveillance
172 in a patient population reveals differences in virus exposure and antibody-mediated immunity
173 according to host demography and healthcare setting. *J Infect Dis*. 2021;223(6):971–980.
- 174 12. Office for National Statistics. Coronavirus (COVID-19) Infection Survey, antibody data for the UK
175 [Internet]. ONS. 2021 [cited 2021 Feb 25]. Available from:

176 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddis](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveyantibodydatafortheuk/16february2021)
177 [eases/articles/coronaviruscovid19infectionsurveyantibodydatafortheuk/16february2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveyantibodydatafortheuk/16february2021)


178

179

180 **Table 1.** Sensitivities and specificities of the assays used to test samples for antibodies to SARS-CoV-2

Assay	Sensitivity (95% CI)	Specificity (95% CI)	Samples tested
Abbott	95.5% (95% CI 90.4%-98.3%)	99.8% (98.8%-100.0%)	Antenatal
DiaSorin	87.5% (95% CI 78.2%-93.8%)	98.6% (95%CI 97.0%-99.5%)	Primary care
Roche	92.3% (95% CI 85.4%-96.6%)	100% (95% CI 98.7%-100.0%)	Antenatal
Siemens	98.5% (95% CI 95.7%-99.7%)	100% (95% CI 98.4%-100.0%)	Antenatal

181



182

183 **Figure 1.** Comparison of (a) 5-weekly rolling SARS-CoV-2 seroprevalence by source of residual samples
 184 with (b) confirmed weekly SARS-CoV-2 PCR positives reported to Public Health Scotland. Dashed lines
 185 indicate 95% confidence intervals. SARS-CoV-2 PCR positives have been plotted against ISO week +3 on
 186 the x-axis to account for the delay between exposure to the virus (infection) and formation of antibodies
 187 (seroconversion).

188

189 **SUPPLEMENTARY FILES**

190 **Table S1.** Adjusted Mantel-Haenszel odds ratios for the association between covariates and SARS-CoV-2
 191 seroprevalence: data from residual samples obtained from primary care across Scotland^a

Model	Covariate	AOR _{MH} (95% CI)	p-value
1 (Sex)	Male	1 (Ref)	
	Female	1.01 (0.91-1.12)	0.8318
2 (Age group)	0-19 years	1 (Ref)	
	20-39 years	0.74 (0.64-0.86)	<0.001
	40-59 years	0.89 (0.77-1.03)	0.1104
	60+ years	0.80 (0.69-0.91)	0.0013
3 (Regional urban/rural classification)	Urban	1 (Ref)	
	Rural	0.70 (0.61-0.79)	<0.001


192 AOR_{MH} = adjusted Mantel-Haenszel odds ratio; CI = confidence interval

193 ^aAll models have been adjusted for ISO-week

194

195


196



197

198 **Figure S1.** 5-weekly rolling SARS-CoV-2 seroprevalence by sex: data from residual samples obtained from
 199 primary care across Scotland. Dashed lines indicate 95% confidence intervals.

200




201

202 **Figure S2.** 5-weekly rolling SARS-CoV-2 seroprevalence by age group: data from residual samples

203 obtained from primary care across Scotland. Dashed lines indicate 95% confidence intervals.


204



205

206 **Figure S3.** 5-weekly rolling SARS-CoV-2 seroprevalence by NHS Board (restricted to NHS Boards with a
 207 large urban population): data from residual samples obtained from primary care across Scotland.

208



209

210 **Figure S4.** 5-weekly rolling SARS-CoV-2 seroprevalence by NHS Board (NHS Boards with primarily rural
 211 populations): data from residual samples obtained from primary care across Scotland.